NorthStar Medical Radioisotopes has entered into a strategic supply agreement with BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research, the company announced today.

According to a release, the agreement will provide BIOEMTECH’S customers with access to AC-225, with a goal of accelerating preclinical radiopharmaceutical development.

“NorthStar is committed to expanding Ac-225 supply for the growing radiopharmaceutical market,” NorthStar Medical Radioisotopes President and CEO Frank Scholz said in a statement. “Working with BIOEMTECH to support preclinical researchers aligns with our mission to advance global access to radiopharmaceuticals with dependable isotope supply with the required quality and regulatory standards.”

The financial terms of the agreement were not disclosed.